Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment

NCT01486264 is registered in ClinicalTrials.gov with Merz Pharmaceuticals GmbH as lead sponsor.

NCT NCT01486264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01486264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment
Lead sponsor
Merz Pharmaceuticals GmbH
Phase
Phase 4
Overall status
Completed
Start date
January 20, 2012
Completion date
March 29, 2016
Enrollment
283 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

cervical dystonia